drugset / Trial / NCT01025206

A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma

NCT01025206 ↗

Phase 1 Completed 35 enrolled BioInvent International AB
NaSingle-groupOpen-labelTreatment

Summary

This is a first in human study which will assess the safety and tolerability of a monoclonal antibody against ICAM-1 in patients with Multiple Myeloma. The tumour response rate will also be measured.

Timeline

Start
2009-12
Primary completion
2013-02
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Subject BI-505 Monoclonal antibody 0.0004 mg/kg Intravenous
Subject BI-505 Monoclonal antibody 20 mg/kg Intravenous

Indications